[go: up one dir, main page]

WO2004039332A3 - Methods for using osteocalcin - Google Patents

Methods for using osteocalcin Download PDF

Info

Publication number
WO2004039332A3
WO2004039332A3 PCT/US2003/034852 US0334852W WO2004039332A3 WO 2004039332 A3 WO2004039332 A3 WO 2004039332A3 US 0334852 W US0334852 W US 0334852W WO 2004039332 A3 WO2004039332 A3 WO 2004039332A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteocalcin
methods
polynucleotides
relates
invention further
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/034852
Other languages
French (fr)
Other versions
WO2004039332A2 (en
Inventor
George Mbella Ekema
Robert W Mays
Kurt R Brunden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athersys Inc
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/283,656 external-priority patent/US20040082018A1/en
Application filed by Athersys Inc filed Critical Athersys Inc
Priority to AU2003294241A priority Critical patent/AU2003294241A1/en
Publication of WO2004039332A2 publication Critical patent/WO2004039332A2/en
Anticipated expiration legal-status Critical
Publication of WO2004039332A3 publication Critical patent/WO2004039332A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for using osteocalcin. The invention also relates to methods for using polynucleotides encoding osteocalcin. The invention relates to methods using the osteocalcin polypeptides and polynucleotides as a target for diagnosis and treatment osteocalcin related conditions. The invention further relates to drug-screening methods using the osteocalcin polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the osteocalcin polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the osteocalcin polypeptides and polynucleotides as a target. The invention further related to methods of treating a subject suffering from an osteocalcin mediated condition.
PCT/US2003/034852 2002-10-28 2003-10-28 Methods for using osteocalcin Ceased WO2004039332A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003294241A AU2003294241A1 (en) 2002-10-28 2003-10-28 Methods for using osteocalcin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42186902P 2002-10-28 2002-10-28
US60/421,869 2002-10-28
US10/283,656 US20040082018A1 (en) 2002-10-29 2002-10-29 Methods for using osteocalcin
US10/283,656 2002-10-29

Publications (2)

Publication Number Publication Date
WO2004039332A2 WO2004039332A2 (en) 2004-05-13
WO2004039332A3 true WO2004039332A3 (en) 2007-08-23

Family

ID=32233092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034852 Ceased WO2004039332A2 (en) 2002-10-28 2003-10-28 Methods for using osteocalcin

Country Status (2)

Country Link
AU (1) AU2003294241A1 (en)
WO (1) WO2004039332A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190697A1 (en) 2006-09-13 2010-07-29 The Trustees Of Columbia University In The City If Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
WO2010104882A1 (en) * 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506111A (en) * 1989-02-10 1996-04-09 Teijin Limited Method of immunological assaying of human osteocalcin, reagent and kit therefor, antibody to human osteocalcin, hybridoma producing said antibody, and method of producing it

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506111A (en) * 1989-02-10 1996-04-09 Teijin Limited Method of immunological assaying of human osteocalcin, reagent and kit therefor, antibody to human osteocalcin, hybridoma producing said antibody, and method of producing it

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BODINE P.V.N. ET AL.: "Evidence that Conditionally Immortalized Human Osteoblasts Express an Osteocalcin Receptor", BONE, vol. 25, no. 5, November 1999 (1999-11-01), pages 535 - 543 *
CHANG W. ET AL.: "Extracellular Ca2+-Sensing Receptors Modulate Matrix Production and Mineralization in Chondrogenic RCJ3.1C5.18 Cells", ENDOCRINOLOGY, vol. 143, no. 4, April 2002 (2002-04-01), pages 1467 - 1474 *
JORTIKKA L. ET AL.: "Use of Myoblasts in Assaying the Osteoinductivity of Bone Morphogenetic Proteins", LIFE SCI., vol. 62, no. 26, 1998, pages 2359 - 2368 *

Also Published As

Publication number Publication date
AU2003294241A1 (en) 2004-05-25
WO2004039332A2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005001061A3 (en) Polynucleotides encoding novel adiponectin receptor variants
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2004083388A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2003048323A3 (en) Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2004039332A3 (en) Methods for using osteocalcin
WO2004051280A3 (en) Identification of agonistic autoantibodies
WO2004083381A3 (en) Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
WO2004094621A3 (en) Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
EP1741792A4 (en) NEW LIGAND OF G PROTEIN CONJUGATED RECEPTOR PROTEIN AND USE THEREOF
WO2002094990A3 (en) Receptors and membrane-associated proteins
WO2001036605A3 (en) 2786, a human aminopeptidase
WO2005097826A3 (en) Prokineticin 2beta peptide and its use
WO2004009797A3 (en) Protein modification and maintenance molecules
WO2001000811A3 (en) 17867, a novel human aminopeptidase
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2001023590A3 (en) 22196, a novel human aminopeptidase
WO2001064858A3 (en) 25312, a human agmatinase-like homolog
WO2004090097A3 (en) Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2003018066A3 (en) A murine genomic polynucleotide sequence encoding a g-protein coupled receptor and methods of use therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004548637

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003294241

Country of ref document: AU

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP